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In this report, we present a rare association between Ebstein anomaly (EA) and isovaleric acidemia (IVA) in a
newborn who was admitted to our cardiac center. He underwent for PDA stenting to maintain adequate pulmonary
blood flow, later he developed recurrent metabolic acidosis, prominent sweaty feet odor, neutropenia and
thrombocytopenia. His organic acids profile in the urine confirmed the diagnosis of IVA.
To the best of our knowledge, there is no association between these two rare diseases. We are presenting this
case report to highlight this rare association.
 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
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Ebstein’s anomaly (EA) is a congenital heartdisease characterized primarily by abnormal-
ities of the tricuspid valve (TV), right atrium (RA)
and right ventricle (RV). The estimated risk of Eb-
stein’s anomaly in the general population is one in
200,000 live births [1]. In newborns with this
anomaly, tricuspid valve regurgitation may be sig-
nificant as it can result in ineffective RV contractil-
ity that is unable to generate forward enough force
to open the pulmonary valve in systole, thus
producing ‘functional’ pulmonary atresia [2]. Iso-valeric acidemia (IVA) is known as one of the
‘classical’ organic acidemias, and is caused by a
genetic deficiency of isovaleryl-CoA dehydroge-
nase catalyzing the third step in leucine catabo-
lism [3].
In this report, we describe one of the rare asso-
ciations between EA and IVA diagnosed in an in-
fant admitted to our center.Case presentation
A two-day male newborn (3.9 kg) was admitted
to our Pediatric Cardiac Intensive Care Unit.
Figure 1. Trans thoracic echocardiography with Doppler showing tricuspid valve regurgitation. ⁄ Tricuspid valve regurgitation, LV: Left
ventricle, RV: Right ventricle, RA: Right atrium.
Figure 2. CXR after PDA stenting.
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EBSTEIN CARDIAC ANOMALY, FUNCTIONAL
PULMONARY ATRESIA AND ISOVALERIC ACIDEMIA:
A CASE REPORTDiagnosed with cyanotic congenital heart disease,
he was placed on prostaglandin E1 (PGE1) for fur-
ther diagnosis and management, and intubated
shortly after that. His chest X-ray examination
showed cardiomegaly. Trans-thoracic echocardi-
ography (TTE) confirmed diagnosis of Ebstein’s
anomaly, functional pulmonary atresia, and pat-
ent ductus arteriosus (PDA) with systemic to pul-
monary shunt through PDA (Fig. 1). The patient
was found to be dependent on PDA, and a trial
of weaning from PGE1 lead to significant desatu-
ration. He was hemodynamically stable with
PGE1 infusion, and was maintained on 70–85%
oxygen saturation.
The patient underwent PDA stenting by inter-
ventional cardiac catheterization on day 10 of life
in order to maintain adequate pulmonary flow
through PDA and to allow liberation from PGE1
infusion. Following successful PDA stenting and
liberation from PGE1, the patient was weaned
from the ventilator, and PGE1 infusion was
stopped completely with no hemodynamic com-
promise or desaturation. Saturation was main-
tained with normal pulmonary blood flow and
normal lung vascularity (Fig. 2).
During the first 2 weeks of life, attempts to initi-
ate feeding were unsuccessful due to both hemo-
dynamic instability and to intolerance of enteralfeeding. After extubation, feeding was established
with regular baby formula. However, within 48 h
of achieving full feeding, the baby started to have
Table 1. Trends of arterial blood gases PH, base excess, blood WBC counts, and platelets counts during pediatric cardiac intensive
care course, showing neutropenia after third week of life and persistent thrombocytopenia after second week of life.
Day 1 Day 5 Day 10 Day 15 Day 20 Day 25 Day 30 Day 35 Day 37
PH 7.35 7.43 7.37 7.34 7.33 7.36 7.32 7.20 7.09
Base Excess (mmol/L) 3.9 3 0.9 8.9 5.7 3.4 2.5 14 15.4
WBC (x103/ml) 21 11.3 9.6 9.2 3.4 3.2 1.7 1.3 1.4
PLT (x103/ml) 241 220 195 97 54 22 28 41 9
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lethargic with episodes of jitteriness coupled with
hypocalcemia, feeding intolerance, and persistent
metabolic acidosis. The patient had also devel-
oped neutropenia, and thrombocytopenia
(Table 1). Septic workup was completed, repeat-
edly demonstrating no evidence of infection dur-
ing the first 4 weeks of life.
During his intensive care stay, the patient
started to give off a distinctively foul odor, similar
to ‘sweaty feet’, despite good hygiene. The odor
coincided with the patient’s feeding initiation dur-
ing the second week of life. Organic acidemia was
suspected. Serum ammonia level was found to be
within normal limits but urine organic acid profile
was positive and showed highly elevated levels of
isovalerylglycine and 3-hydroxyisovaleric, consis-
tent with isovaleric acidemia. Based on these re-
sults, the patient was started on carnitine and
given parenteral nutrition. Glycine was unavail-
able in our hospital. Subsequently, overwhelming
sepsis developed after 1 month, and the patient
deteriorated due to overwhelming refractory sep-
tic shock with Klebsiella pneumonia. He suc-
cumbed at day 37 of life. Pre-mortal blood
sample had been obtained to analyze the gene
responsible for IVA, and genetic counseling for
the family of the deceased ensued.Discussion
Tanaka and associates were the first to recognize
and describe isovaleric acidemia in 1966 [4]. There
is no published data about the prevalence of IVA
in Saudi Arabia. Research shows that IVA is
caused by mutations in the IVD gene, or isovale-
ryl-CoA dehydrogenase [5]. The IVD enzyme is
encoded by the nuclear gene, which is located
on chromosome 15q14-15 [6].
IVA may manifest in acute or chronic intermit-
tent form. Clinical manifestations in the acute
form include vomiting and severe acidosis in the
first few days of life. Lethargy, convulsions, and
coma may ensue. Death may follow if proper ther-
apy is not initiated. A characteristic odor of
‘sweaty feet’ may be present [7]. This odor was aprominent sign in our patient, and led us to start
investigations for IVA.
Infants who survive this acute episode will go
onto have the chronic intermittent form later on
in life. A milder form of the chronic intermittent
disease also exists. In both forms, acute episodes
of metabolic decompensation may occur during
a catabolic state such as an infection [7].
We think that three factors possibly delayed
clinical manifestations of IVA in our patient.
These were the use of IV fluid since birth, delayed
feeding, and the frequent replacements of sodium
bicarbonate, attributed initially to inadequate car-
diac output secondary to heart disease.
Laboratory findings during the acute attacks in-
clude ketoacidosis, neutropenia, thrombocytope-
nia and, occasionally, pancytopenia due to bone
marrow suppression. Hypocalcaemia, hyperglyce-
mia and moderate to severe hyperammonemia
may be present in some patients [7]. All the above
listed laboratory findings were found in our pa-
tient except ammonia level, which remained with-
in normal levels.
Diagnosis of IVA is established by demonstrat-
ing marked elevations of isovaleric acid and its
metabolites in body fluids, especially in urine, as
first described in 1967 [8]. We based our patient
diagnosis on urine tests, which repeatedly showed
highly positive results.
Isovaleric acidemia is inherited as an autosomal
recessive trait [6]. Our patient was the firstborn to
his parents, and this disease was not previously
diagnosed in either family.
Treatment of the acute attack targets hydration,
reversal of the catabolic state by providing ade-
quate calories orally or intravenously, correction
of metabolic acidosis, and removal of the excess
isovaleric acid.
Isovalerylglycine has a high urinary clearance,
and therefore administration of glycin is
recommended to enhance formation of
isovalerylglycine.
L-carnitine also increases removal of isovaleric
acid by forming isovalerylcarnitine, which is ex-
creted in the urine. Our patient received L-carni-
tine directly after confirmation of IVA.
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EBSTEIN CARDIAC ANOMALY, FUNCTIONAL
PULMONARY ATRESIA AND ISOVALERIC ACIDEMIA:
A CASE REPORTThe etiology of Ebstein’s anomaly is unknown.
However, in rare cases, genetic factors such as
mutations in the transcription factor NKX2.5,
10p13-p14 deletion and 1p34.3-p36.11 deletion
are described [1]. Newborns with severe forms
of Ebstein’s anomaly have marked cyanosis and
cardiomegaly, while the majority are dependent
on a PDA patency for pulmonary blood flow [9].
Our patient was PDA dependent, and needed
PGE1 to maintain ductus arteriosus patency.
Metabolic disorders are reported in association
with some cardiac anomalies, mainly myopathy
and cardiomyopathy. These may include glyco-
gen storage diseases, disorders of lipid metabo-
lism such as carnitine deficiency, disorders of
mitochondrial metabolism and other storage dis-
orders such mucopolysaccharidosis. Organic
acidemias are rarely reported with cardiac abnor-
mality [10]. In methylmalonic acidemia, hypertro-
phic and dilated cardiomyopathy have been
described [11].
Furthermore, dilated cardiomyopathy is also a
frequent complication reported in association with
propionic acidemia (PA) [12].
To the best of our knowledge, there is no re-
ported association between isovaleric acidemia
and congenital heart disease in medical literature.
In conclusion, congenital heart disease may oc-
cur in association with metabolic disorder.
Although this association is rare, it should not be
overlooked, particularly in cases of unexplained
acidemia or other investigations that cannot be
attributed to congenital heart problems. Further
genetic studies are needed to explore the possible
association of specific heart lesions with certain
metabolic diseases.References
[1] Krieger EV, Valente AM. Diagnosis and management of
Ebstein anomaly of the tricuspid valve. Curr Treat Options
Cardiovasc Med 2012;14(6):594–607.
[2] Suzuki H, Nakasato M, Sato S, Komatsu H, Hayasaka K.
Management of functional pulmonary atresia with
isoproterenol in a neonate with Ebstein’s anomaly.
Tohoku J Exp Med 1997;181(4):459–65.
[3] Ensenauer R, Vockley J, Willard JM, Huey JC, Sass JO,
Edland SD, et al. A common mutation is associated with a
mild, potentially asymptomatic phenotype in patients with
isovaleric acidemia diagnosed by newborn screening. Am
J Hum Genet 2004;75(6):1136–42.
[4] Tanaka K, Budd MA, Efron ML, Isselbacher KJ. Isovaleric
acidemia: a new genetic defect of leucine metabolism. Proc
Natl Acad Sci U S A 1966;56(1):236–42.
[5] Ensenauer R, Fingerhut R, Maier EM, Polanetz R,
Olgemöller B, Röschinger W, et al. Newborn screening
for isovaleric acidemia using tandem mass spectrometry:
data from 1.6 million newborns. Clin Chem
2011;57(4):623–6.
[6] Hertecant JL, Ben-Rebeh I, Marah MA, Abbas T, Ayadi L,
Ben Salem S, et al. Clinical and molecular analysis of
isovaleric acidemia patients in the United Arab Emirates
reveals remarkable phenotypes and four novel mutations
in the IVD gene. Eur J Med Genet 2012;55(12):671–6.
[7] Dercksen M, Duran M, Ijlst L, Mienie LJ, Reinecke CJ,
Ruiter JP, et al. Clinical variability of isovaleric acidemia in
a genetically homogeneous population. J Inherit Metab
Dis 2012;35(6):1021–9.
[8] Tanaka K, Isselbacher KJ. The isolation and identification
of N-isovalerylglycine from urine of patients with
isovaleric acidemia. J Biol Chem 1967;242(12):2966–72.
[9] Bove EL, Hirsch JC, Ohye RG, Devaney EJ. How I manage
neonatal Ebstein’s anomaly. Semin Thorac Cardiovasc
Surg Pediatr Card Surg Annu 2009;12(1):63–5.
[10] Gilbert-Barness E. Review: metabolic cardiomyopathy and
conduction system defects in children. Ann Clin Lab Sci
2004;34(1):15–34.
[11] Prada CE, Al Jasmi F, Kirk EP, Hopp M, Jones O, Leslie
ND, et al. Cardiac disease in methylmalonic acidemia. J
Pediatr 2011;159(5):862–4.
[12] Romano S, Valayannopoulos V, Touati G, Jais JP, Rabier D,
de Keyzer Y, et al. Cardiomyopathies in propionic aciduria
are reversible after liver transplantation. J Pediatr
2010;156(1):128–34.
